Pacira BioSciences
PCRX
130 hedge funds and large institutions have $1.69B invested in Pacira BioSciences in 2013 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 47 increasing their positions, 45 reducing their positions, and 12 closing their positions.
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
69% more capital invested
Capital invested by funds: $994M → $1.69B (+$691M)
30% more call options, than puts
Call options by funds: $7.49M | Put options by funds: $5.77M
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 116 → 130 (+14)
4% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.3M |
| 4 |
DCM
Daruma Capital Management
New York
|
+$15.3M |
| 5 |
CCM
Century Capital Management
Boston,
Massachusetts
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$38.9M |
| 2 |
VAM
Visium Asset Management
New York
|
-$37.4M |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$15.7M |
| 4 |
O
OrbiMed
New York
|
-$14.4M |
| 5 |
PWPCM
Perella Weinberg Partners Capital Management
New York
|
-$12.9M |
PCRX Hedge Fund Activity: Q3 2013 in Review
130 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2013, worth a combined $1.69B — up 69% from $994M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PCRX positions and 12 closed out — a net gain of 15 holders — while 47 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $38.9M.
- 130 institutional investors held Pacira BioSciences (PCRX) as of Q3 2013, up from 116 in Q2 2013.
- Funds reported $1.69B of Pacira BioSciences stock for Q3 2013, up 69% quarter-over-quarter.
- 27 funds opened new Pacira BioSciences positions in Q3 2013 and 12 closed out, a net change of +15 holders.
- The largest Pacira BioSciences buyer in Q3 2013 was Fidelity Investments, an estimated $28.7M added.
- The largest Pacira BioSciences seller in Q3 2013 was T. Rowe Price Associates, an estimated $38.9M sold.
Based on aggregated 13F filings for Q3 2013.